Advanced search

Vol 57, No 6 (2023)
Research Paper
Published online: 2023-11-13

open access

View PDF Download PDF file
Page views 717
Article views/downloads 479
Get Citation

Connect on Social Media

Connect on Social Media

Reversing dabigatran effect with idarucizumab to enable intravenous thrombolysis in patients with acute ischaemic stroke — a single centre experience

Ewa Włodarczyk1, Katarzyna Sawczyńska12, Paweł Wrona12, Agnieszka Słowik12
DOI: 10.5603/pjnns.96469
Pubmed: 37955597
Neurol Neurochir Pol 2023;57(6):465-476.

Abstract

Introduction. Our study analysed the safety and effectiveness of idarucizumab in enabling intravenous thrombolysis (IVT) in dabigatran-treated patients with acute ischaemic stroke (AIS).

Clinical rationale for the study. New oral anticoagulants (NOAC), including dabigatran, are the first-choice treatment option for preventing ischaemic stroke in patients with non-valvular atrial fibrillation (AF). However, a significant percentage of AF patients develops AIS despite NOAC treatment. According to current guidelines, treatment with IVT is contraindicated in patients who have received NOAC within the last 48 hours. Idarucizumab is a fragment of a monoclonal antibody that reverses the anticoagulation effect of dabigatran. The latest research shows that it can enable safe and successful IVT in patients with recent dabigatran intake, but more data is needed to confirm the safety and effectiveness of such treatment.

Material and methods. Our study included dabigatran-treated patients who received idarucizumab to allow AIS treatment with IVT in the University Hospital in Kraków (Poland) from December 2018 to June 2023. We gathered data on their past medical history, stroke severity, course of treatment and outcomes as defined by modified Rankin Scale (mRS) and National Institutes of Health Stroke Scale (NIHSS) scores at discharge. A good functional outcome was defined as mRS 0–2 points at discharge.

Results. This observational study included 19 patients (13 male and six female) with a median age of 74 (IQR = 13) years. In all patients (100%), the reason for dabigatran treatment was AF. A good functional outcome after treatment (mRS 0–2) was achieved in 68.4% of patients, but mRS was already ≥ 3 points before stroke onset in three (15.8%) patients. Haemorrhagic transformation of stroke occurred in three (15.8%) patients, including symptomatic intracranial haemorrhage in two (10.5%). The mortality rate was 5.3%.

Conclusions and clinical implications. Our study results are in line with previous research on this topic, showing that IVT after idarucizumab can be successfully administered and is reasonably safe in dabigatran-treated patients with AIS.

Keywords: acute ischaemic strokeintravenous thrombolysisidarucizumabdabigatrannew oral anticoagulants

Article available in PDF format

View PDF Download PDF file

References

  1. Katan M, Luft A. Global Burden of Stroke. Semin Neurol. 2018; 38(2): 208–211.
    CrossRefPubMed
  2. Khatri P, Abruzzo T, Yeatts SD, et al. IMS I and II Investigators. Good clinical outcome after ischemic stroke with successful revascularization is time-dependent. Neurology. 2009; 73(13): 1066–1072.
    CrossRefPubMed
  3. Saraiva JF. Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices. Cardiol Ther. 2018; 7(1): 15–24.
    CrossRefPubMed
  4. Bang OhY, Park KM, Jeong DS. Occurrence of Ischemic Stroke in Patients With Atrial Fibrillation Receiving Non-Vitamin K Oral Anticoagulants: Causes and Prevention Strategies. J Stroke. 2023; 25(2): 199–213.
    CrossRefPubMed
  5. Berge E, Whiteley W, Audebert H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J. 2021; 6(1): I–LXII.
    CrossRefPubMed
  6. Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal — Full Cohort Analysis. N Engl J Med. 2017; 377(5): 431–441.
    CrossRefPubMed
  7. Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41(2): 255–323.
    CrossRefPubMed
  8. Zhang Y, Song S, Li Z, et al. The Application of Software "Rapid Processing of Perfusion and Diffusion" in Acute Ischemic Stroke. Brain Sci. 2022; 12(11).
    CrossRefPubMed
  9. Morinaga Y, Nii K, Takemura Y, et al. Types of intraparenchymal hematoma as a predictor after revascularization in patients with anterior circulation acute ischemic stroke. Surg Neurol Int. 2021; 12: 102.
    CrossRefPubMed
  10. Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42(5): 373–498.
    CrossRefPubMed
  11. Hankey GJ, Norrving Bo, Hacke W, et al. Management of acute stroke in patients taking novel oral anticoagulants. Int J Stroke. 2014; 9(5): 627–632.
    CrossRefPubMed
  12. Auer E, Frey S, Kaesmacher J, et al. Stroke severity in patients with preceding direct oral anticoagulant therapy as compared to vitamin K antagonists. J Neurol. 2019; 266(9): 2263–2272.
    CrossRefPubMed
  13. Eikelboom J, Quinlan D, Ryn Jv, et al. Idarucizumab. Circulation. 2015; 132(25): 2412–2422.
    CrossRef
  14. Cuker A, Burnett A, Triller D, et al. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. Am J Hematol. 2019; 94(6): 697–709.
    CrossRefPubMed
  15. Błażejewska-Hyżorek B, Czernuszenko A, Członkowska A, et al. Wytyczne postępowania w udarze mózgu. Polski Przegląd Neurologiczny. 2019; 15(A): 1–156.
    CrossRef
  16. Ohya Y, Makihara N, Wakisaka K, et al. Thrombolytic therapy in severe cardioembolic stroke after reversal of dabigatran with idarucizumab: case report and literature review. J Stroke Cerebrovasc Dis. 2018; 27(7): e128–e131.
    CrossRefPubMed
  17. Lin YT, Lai YJ, Lai TH. Idarucizumab for intravenous thrombolysis and endovascular thrombectomy in acute stroke: a case report. J Emerg Med. 2020; 58(3): e113–e116.
    CrossRefPubMed
  18. Baule A, Cabigiosu F, Zanda B, et al. Thrombolysis in Acute Ischemic Stroke after Idarucizumab for Dabigatran Etexilate Reversal in Elderly: A Case Report. J Vasc Interv Neurol. 2018; 10(2): 15–17.
    PubMed
  19. Xie D, Wang X, Li Y, et al. Intravenous thrombolysis after reversal of dabigatran with idarucizumab in acute ischemic stroke: a case report. Front Aging Neurosci. 2021; 13: 765037.
    CrossRefPubMed
  20. Bissig D, Manjunath R, Traylor BR, et al. Acute stroke despite dabigatran anticoagulation treated with idarucizumab and intravenous tissue plasminogen activator. J Stroke Cerebrovasc Dis. 2017; 26(6): e102–e104.
    CrossRefPubMed
  21. Harsha KJ, Thirunavukkarasu S, Butcher K. Acute stroke thrombolysis following dabigatran reversal using idarucizumab. Neurol India. 2019; 67(2): 568–570.
    CrossRefPubMed
  22. Meyer D, Chu F, Derry K, et al. Acute reversal of dabigatran with Idarucizumab for intravenous thrombolysis as acute stroke treatment. J Clin Neurosci. 2019; 59: 355–357.
    CrossRefPubMed
  23. Loh CH, Herkes G. Republished: Successful thrombolysis for acute ischaemic stroke after reversal of dabigatran etexilate with idarucizumab. Drug Ther Bull. 2019; 57(9): 141–143.
    CrossRefPubMed
  24. Vukorepa G, Deveđija S, Crnjaković M, et al. Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window. Turk J Emerg Med. 2020; 20(2): 90–92.
    CrossRefPubMed
  25. Tireli D, He J, Nordling MM, et al. Systemic thrombolysis in acute ischemic stroke after dabigatran etexilate reversal with idarucizumab — a case report. J Stroke Cerebrovasc Dis. 2017; 26(7): e123–e125.
    CrossRefPubMed
  26. Pásztor M, Bereczki D, Szakács Z, et al. Idarucizumab adását követően elvégzett szisztémás thrombolysis akut ischaemiás stroke-ban. Ideggyógyászati szemle. 2017; 70(7-8): 284–288.
    CrossRef
  27. Hieber M, Bardutzky J. Immediate Reversal of Dabigatran by Idarucizumab Prior to Laboratory and Imaging Results in Acute Stroke. Front Neurol. 2019; 10: 230.
    CrossRefPubMed
  28. Hosoki S, Takagi M, Yamagami H, et al. Paradoxical elevation of plasma dabigatran after reversal with idarucizumab in stroke thrombolysis. J Neurol. 2018; 265(10): 2451–2453.
    CrossRefPubMed
  29. Alvarez Bravo G, Orts Castro E, Carvalho Monteiro G, et al. Intravenous fibrinolysis in ischemic stroke of large vessel after reversing effect of dabigatran with idarucizumab. J Stroke Cerebrovasc Dis. 2017; 26(9): e192–e193.
    CrossRefPubMed
  30. Jala S, O'Brien E. Treatment with intravenous alteplase for acute ischemic stroke after reversal of dabigatran with idarucizumab: a case study. J Neurosci Nurs. 2019; 51(1): 21–25.
    CrossRefPubMed
  31. Wowern Fv, Brizzi M, Holst J. Reversal of the Anticoagulation Effects of Dabigatran Etexilate by Idarucizumab in Three Patients Needing Urgent Surgical Intervention and One Case of Intravenous Thrombolysis in Ischaemic Stroke. Eur J Case Rep Intern Med. 2017; 4(4): 000569.
    CrossRefPubMed
  32. Binet Q, Hammer FD, Rocrelle O, et al. Systemic thrombolysis and endovascular thrombectomy in severe acute ischemic stroke after dabigatran reversal with idarucizumab. Clin Case Rep. 2018; 6(4): 698–701.
    CrossRefPubMed
  33. Agosti S, Casalino L, Rocci E, et al. Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report. J Med Case Rep. 2017; 11(1): 224.
    CrossRefPubMed
  34. Mutzenbach JS, Pikija S, Otto F, et al. Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab - a case report. Ann Clin Transl Neurol. 2016; 3(11): 889–892.
    CrossRefPubMed
  35. Ohtani T, Sintoku R, Yajima T, et al. Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report. J Med Case Rep. 2019; 13(1): 390.
    CrossRefPubMed
  36. Vene N, Mavri A, Božič-Mijovski M, et al. Idarucizumab for dabigatran reversal in daily clinical practice: A case series. Eur J Anaesthesiol. 2020; 37(10): 874–878.
    CrossRefPubMed
  37. Schäfer N, Müller A, Wüllner U. Systemic thrombolysis for ischemic stroke after antagonizing dabigatran with idarucizumab-a case report. J Stroke Cerebrovasc Dis. 2016; 25(8): e126–e127.
    CrossRefPubMed
  38. Lo WT, Ng KF, Chan SCh, et al. Intravenous stroke thrombolysis after reversal of dabigatran effect by idarucizumab: first reported case in Hong Kong. Hong Kong Med J. 2018; 24(1): 81–83.
    CrossRefPubMed
  39. Berrouschot J, Stoll A, Hogh T, et al. Intravenous thrombolysis with recombinant tissue-type plasminogen activator in a stroke patient receiving dabigatran anticoagulant after antagonization with idarucizumab. Stroke. 2016; 47(7): 1936–1938.
    CrossRefPubMed
  40. Haastrup SB, Hellfritzsch M, Nybo M, et al. Real-world experience with reversal of dabigatran by idarucizumab. Thromb Res. 2021; 197: 179–184.
    CrossRefPubMed
  41. Schulz JG, Kreps B. Idarucizumab elimination of dabigatran minutes before systemic thrombolysis in acute ischemic stroke. J Neurol Sci. 2016; 370: 44.
    CrossRefPubMed
  42. Laxamana LC, Co CO, Yu JR, et al. Dabigatran reversal with idarucizumab preceding thrombolysis in an octogenarian patient with chronic kidney disease and acute stroke: a case report. Clin Ther. 2020; 42(9): 1840–1845.
    CrossRefPubMed
  43. Gawehn A, Ayari Y, Heuschkel C, et al. Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report. J Med Case Rep. 2016; 10(1): 269.
    CrossRefPubMed
  44. Turine G, Peeters A, Hermans C, et al. Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a moment to be a pioneer. Acta Neurol Belg. 2017; 117(3): 753–755.
    CrossRefPubMed
  45. Kikule I, Baborikina A, Haritoncenko I, et al. Idarucizumab in dabigatran-treated patients with acute ischemic stroke receiving thrombolytic therapy. Medicina (Kaunas). 2022; 58(10).
    CrossRefPubMed
  46. Kermer P, Eschenfelder CC, Diener HC, et al. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection. Int J Stroke. 2017; 12(4): 383–391.
    CrossRefPubMed
  47. Kermer P, Eschenfelder CC, Diener HC, et al. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany — A national case collection. Int J Stroke. 2017; 12(4): 383–391.
    CrossRefPubMed
  48. Fang CW, Tsai YT, Chou PC, et al. Intravenous thrombolysis in acute ischemic stroke after idarucizumab reversal of dabigatran effect: analysis of the cases from taiwan. J Stroke Cerebrovasc Dis. 2019; 28(3): 815–820.
    CrossRefPubMed
  49. Pretnar Oblak J, Sabovic M, Frol S. Intravenous thrombolysis after idarucizumab application in acute stroke patients-a potentially increased sensitivity of thrombi to lysis? J Stroke Cerebrovasc Dis. 2019; 28(3): 768–773.
    CrossRefPubMed
  50. Hieber M, Hollasch H, Heck D, et al. Reversal of dabigatran using idarucizumab: single center experience in four acute stroke patients. J Thromb Thrombolysis. 2018; 46(1): 12–15.
    CrossRefPubMed
  51. Šaňák D, Jakubíček S, Černík D, et al. Intravenous thrombolysis in patients with acute ischemic stroke after a reversal of dabigatran anticoagulation with idarucizumab: a real-world clinical experience. J Stroke Cerebrovasc Dis. 2018; 27(9): 2479–2483.
    CrossRefPubMed
  52. Tsai LK, Lin HJ, Chua SK, et al. Real-world experience with idarucizumab to reverse anticoagulant effect in dabigatran-treated patients: report of 11 cases from taiwan. J Stroke Cerebrovasc Dis. 2018; 27(2): e27–e33.
    CrossRefPubMed
  53. Vosko MR, Bocksrucker C, Drwiła R, et al. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases. J Thromb Thrombolysis. 2017; 43(3): 306–317.
    CrossRefPubMed
  54. Amin S, Kasischke KA, Elsayed K, et al. No time to lose: cases of anticoagulant reversal before thrombolysis in acute ischemic stroke patients. Cureus. 2022; 14(1): e21406.
    CrossRefPubMed
  55. Amin S, Kasischke KA, Elsayed K, et al. No time to lose: cases of anticoagulant reversal before thrombolysis in acute ischemic stroke patients. Cureus. 2022; 14(1): e21406.
    CrossRefPubMed
  56. Giannandrea D, Caponi C, Mengoni A, et al. Intravenous thrombolysis in stroke after dabigatran reversal with idarucizumab: case series and systematic review. J Neurol Neurosurg Psychiatry. 2019; 90(5): 619–623.
    CrossRefPubMed
  57. Maramattom BV, Thomas J. Reversal of anticoagulation effect of dabigatran with idarucizumab, for thrombolysis in acute ischemic stroke: inimicus inimico amicus. Ann Indian Acad Neurol. 2019; 22(4): 515–517.
    CrossRefPubMed
  58. Zhao H, Coote S, Pesavento L, et al. Prehospital idarucizumab prior to intravenous thrombolysis in a mobile stroke unit. Int J Stroke. 2019; 14(3): 265–269.
    CrossRefPubMed
  59. Beharry J, Waters MJ, Drew R, et al. Dabigatran reversal before intravenous tenecteplase in acute ischemic stroke. Stroke. 2020; 51(5): 1616–1619.
    CrossRefPubMed
  60. Kafke W, Kraft P. Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a case report. Case Rep Neurol. 2016; 8(2): 140–144.
    CrossRefPubMed
  61. Ng FC, Bice J, Rodda A, et al. Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis. J Neurol. 2017; 264(3): 591–594.
    CrossRefPubMed
  62. Tsai YT, Hsiao YJ, Tsai LK, et al. Idarucizumab-facilitated intravenous thrombolysis in acute stroke with dabigatran: Two cases with hemorrhagic transformation. J Neurol Sci. 2018; 388: 155–157.
    CrossRefPubMed
  63. Frol S, Sagris D, Pretnar Oblak J, et al. Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature. Front Neurol. 2021; 12: 666086.
    CrossRefPubMed
  64. Romoli M, Matteo E, Migliaccio L, et al. Thrombolysis after dabigatran reversal: A nation-wide Italian multicentre study, systematic review and meta-analysis. Eur Stroke J. 2023; 8(1): 117–124.
    CrossRefPubMed
  65. Frol S, Sernec LP, Hudnik LK, et al. Idarucizumab reversal of dabigatran in patients with acute ischemic stroke and intracranial hemorrhage: comparison with non-idarucizumab-treated patients. CNS Drugs. 2021; 35(2): 233–242.
    CrossRefPubMed
  66. van der Horst SFB, Martens ESL, den Exter PL, et al. Idarucizumab for dabigatran reversal: a systematic review and meta-analysis of indications and outcomes. Thromb Res. 2023; 228: 21–32.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Neurologia i Neurochirurgia Polska

About Via Medica Advertising
Bookstore (Ikamed) TVMed
News
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice